tbuckley/cabot-search huggingface dataset:
Abstract 78: An Incomplete Kawasaki Disease Child With Initial Presentation Of Murmur
Authors: Lucy Y Eun, Yunjung Choi, Mindong Sung, Jo Won Jung, Jae Young Choi
Journal: Circulation (2015)

Abstract: Kawasaki disease(KD) is acute vasculitis in childhood. The authors report the 12-month-old girl with initial presentation of cardiac murmur who was diagnosed incomplete KD. Case: A 12-month-old girl with history of 3 days fever up to 38°C and upper respiratory symptoms including rhinorrhea visited a pediatric clinic. Cardiac murmur was noticed, then she was referred to Pediatric Cardiology clinic. She had loss of appetite and her growth curve showed severely underweight of 8.4kg(less than 3p) compared to height 78cm(50~75p). On hospital day 1, laboratory studies revealed a white blood cell (WBC) 9.4(seg73%, Lym23%)x 103/uL, hemoglobin concentration(Hb) of 5.5 g/dL with hematocrit(Hct) 21%, platelet count 426,000/uL. And laboratory results included ESR 2mm/hr, C-reactive protein 0.05mg/L, AST/ALT 31/19 IU/L, Ferritine 13 ng/mL, TIBC 510ug/dL, Transferrin Saturation Index 2.5% and MCV 50.4fL, MCH 13.4pg, MCHC 26.5g/dL. She had grade II-III/VI end-systolic &amp; early diastolic murmur. The echocardiography showed left main coronary artery dilatation and pericaridial effusion. Based on diagnosis of incomplete Kawasaki disease and iron deficiency anemia, she treated with IVIG(IV gamma globulin), acetylsalicyclic acid, packed RBC transfusion and supplement of oral iron. On hospital day 2, repeat laboratory studies revelaed Hb 6.5 g/dL, and the murmur decreased rapidly. 6 days later Hb was 9.3 g/dL. Pro-BNP was 352 pg/ml on hospital day 1 and repeat studies revealed 978 pg/ml on hospital day 2, 84pg/ml on hospital day 8. The patient was discharged 8 days after admission(on day 11 of her illness) without fever. After 1 month of discharge, she had gained weight to 10.5kg and laboratory study results Hb 11.0 g/dL. And follow-up echorcardiography showed improvement of coronary arteries. The authors report one child presenting with heart murmur under incomplete Kawasaki disease.
Interpreting the Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma
Authors: Hajime Uno, Dae Hyun Kim, Lee-Jen Wei
Journal: JAMA Oncology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
NHS to get funding boost of 3.4% a year over next five years
Authors: Gareth Iacobucci
Journal: BMJ (2018)

The NHS in England will receive an average annual funding increase of 3.4% over the next five years, the prime minister has announced.

The funding boost, announced ahead of the NHS’s 70th birthday on 5 July, followed intense talks between Theresa May, chancellor Philip Hammond, the health and social care secretary for England, Jeremy Hunt, and NHS England’s chief executive, Simon Stevens, in which Hunt and Stevens lobbied hard for extra NHS funding to ease pressure on the service.

In a speech at the Royal Free Hospital in north London on Monday 18 June, May also confirmed that the government and NHS England would agree and publish a detailed 10 year plan later this year, …
Contributions of Screening and Treatment to Mortality From Breast Cancer—Reply
Authors: Sylvia K. Plevritis, Donald A. Berry, Jeanne S. Mandelblatt
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Harms of screening for abdominal aortic aneurysm outweigh benefits, says study
Authors: Susan Mayor
Journal: BMJ (2018)

Screening for abdominal aortic aneurysm has not contributed substantially to reductions in mortality associated with the condition and has increased the risk of avoidable surgery, a study analysing the nationwide screening programme in Sweden has found.1

The study’s lead author, Minna Johansson, from the University of Gothenburg, said, “Previously, the balance between the benefits and harms of screening programmes for abdominal aortic aneurysm was unclear, as the major harms had not been adequately considered. Our new findings suggest that this screening programme may be outdated, because the number of deaths from abdominal aortic aneurysm …
Abstract P067: Longitudinal Association of Self-Reported Sleep-Disordered Breathing and Peripheral Arterial Disease: The Multi-Ethnic Study of Atherosclerosis
Authors: Mako Nagayoshi, Susan Redline, Aaron R Folsom, Eyal Shahar, Hiroyasu Iso, Christina L Wassel, Matthew A Allison, Michael H Criqui, Pamela L Lutsey
Journal: Circulation (2015)

Background: Sleep-disordered breathing (SDB) has been associated with cardiovascular disease risk factors and event occurrence in previous studies. However, the association between SDB and peripher...
Effectiveness and safety of varenicline and nicotine replacement therapy among mental health patients: A retrospective cohort study
Authors: C.A. Jimenez-Ruiz, J.F. Pascual-Lledó, A. Cícero-Guerrero, M. Cristóbal-Fernández, M. Mayayo-Ulibarri, C. Villar-Laguna
Journal: Pulmonology (2017)

To analyse the effectiveness and safety of two smoking cessation medications (varenicline and nicotine patches) in patients with controlled psychiatric disorders in daily practice in a Smoking Cessation Service.
Quadrupling inhaled glucocorticoid dose for deteriorating asthma control reduced severe exacerbations
Authors: Diego J. Maselli, Jay I. Peters
Journal: Annals of Internal Medicine (2018)

ACP Journal Club19 June 2018Quadrupling inhaled glucocorticoid dose for deteriorating asthma control reduced severe exacerbationsDiego J. Maselli, MD, Jay I. Peters, MDDiego J. Maselli, MDUniversity of Texas Health San Antonio, San Antonio, Texas, USA (D.J.M., J.I.P.)Search for more papers by this author, Jay I. Peters, MDUniversity of Texas Health San Antonio, San Antonio, Texas, USA (D.J.M., J.I.P.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2018-168-12-065 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationMcKeever T, Mortimer K, Wilson A, et al. Quadrupling inhaled glucocorticoid dose to abort asthma exacerbations. N Engl J Med. 2018;378:902-10. https://pubmed.ncbi.nlm.nih.gov/29504499Clinical Impact RatingsGIM/FP/GP: Allerg & Immunol: Pulmonology: References1 Global Initiative for Asthma. Global strategy for asthma management and prevention, 2018. http://ginasthma.org/2018-gina-report-global-strategy-for-asthma-management-and-prevention/ (accessed 19 Apr 18). Google Scholar2 Oborne J, Mortimer K, Hubbard RB, et al. Quadrupling the dose of inhaled corticosteroid to prevent asthma exacerbations: a randomized, double-blind, placebo-controlled, parallel-group clinical trial. Am J Respir Crit Care Med. 2009;180:598-602. [PMID: 19590019] Google Scholar Author, Article, and Disclosure InformationAffiliations: University of Texas Health San Antonio, San Antonio, Texas, USA (D.J.M., J.I.P.)This article was published at Annals.org on 5 June 2018. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byIncreased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and childrenReducing asthma hospitalisations in at‐risk children: A systematic review 19 June 2018Volume 168, Issue 12Page: JC65KeywordsAsthmaBronchodilatorsHealth careLungsNumber needed to treatPneumoniaPulmonary medicineRelative riskRisk ratioSerious adverse events ePublished: 19 June 2018 Issue Published: 19 June 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
AB0617 Across-sectional study of nailfold microvascular changes in indian patients with rnp+ lupus and mctd using nailfold videocapillaroscopy
Authors: P.P. Chebbi, R. goel, R. aithal, G. mahasampath, D. danda
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Nailfold Capillary (NFC) changes represent degree of microvascular involvement in autoimmune connective tissue diseases. Anti U1-RNP is associated with specific internal organ involvement in SLE. Nailfold capillaroscopy may objectively predict the systemic microvascular abnormalities in SLE patients with positive Anti U1-RNP antibody. <h3>Objectives</h3> To study nailfold microvascular changes (NFVC) in SLE patients with RNP +and compare them with NFVC changes observed in patients with RNP negative SLE and Mixed connective tissue disease (MCTD). <h3>Methods</h3> Nailfold videocapillaroscopic (NFVC) examination (Optiliamediscope, 200X) was performed in consecutive patients satisfying classification criteria of SLE with or without Anti-U1 RNP positivity. Patients satisfying criteria for MCTD were recruited as disease controls. Individual NFC parameters were analysed by a blinded assessor. Changes in three groups were compared using non-parametric tests. Ordinal logistic or linear regression were used wherever applicable to assess any independent association of NFC changes with disease groups. <h3>Results</h3> Total of 81 patients were studied, of which 28 had SLE with RNP+ (age 30.0±10.37; 26 females), 26 had SLE without RNP positivity (age 29.42±9.20; 25 females) and 26 had MCTD (age37.0±9.86; 25 females). Capillary density was significantly reduced in MCTD as compared to RNP+SLE patients (5.11±1.69/mm vs 7.25±1.38/ mm, p=0.0001), as well as in RNP+SLE as compared to RNP negative SLE patients (7.25±1.38/mm vs 8.92±1.13/mm, p=0.0001). Conversely, patients with RNP+SLE had more frequent giant capillaries, enlarged capillaries and ramified/branched capillaries as compared to RNP negative SLE patients (p=0.047, 0.001 and 0.029 respectively). However, there was no statistical difference in number of haemorrhages among these groups. These changes were more severe in patients with MCTD as compared to RNP+SLE. Ordinal logistic regression showed more severe reduction in capillary density in patients with RNP+SLE as compared to RNP negative SLE (OR=9.5, p=0.007) independent of the presence of Raynaud's, ILD and disease duration. <h3>Conclusions</h3> Presence of anti-U1RNP antibody is associated with micro-vascular abnormalities in SLE as detected by NFVC. Patients with MCTD have more profound abnormalities as compared to RNP +SLE patients. <h3>Disclosure of Interest</h3> None declared
Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy
Authors: Katrijn Broos, Quentin Lecocq, Geert Raes, Nick Devoogdt, Marleen Keyaerts, Karine Breckpot
Journal: Theranostics (2018)

Molecular imaging of the immune checkpoint receptor PD-1 and its ligand PD-L1 is increasingly investigated as a strategy to guide and monitor PD-1:PD-L1-targeted immune checkpoint therapy.We provide an overview of the current state-of-the-art on PD-1-and PD-L1-specific imaging agents for quantitative, real-time assessment of PD-1:PD-L1 expression in the tumor environment and discuss their potential for clinical translation.
Abstract 17026: Serum Adropin Level is Associated With Exercise Training-induced Improvement of Arterial Stiffness in Obese Adults
Authors: Shumpei Fujie, Koji Sato, Natsuki Hasegawa, Satoshi Fujita, Kiyoshi Sanada, Takafumi Hamaoka, Motoyuki Iemitsu
Journal: Circulation (2015)

Introduction: Obesity-induced deterioration of arterial stiffness is reduced by habitual exercise, and increased production of nitric oxide (NO) participates in this effect. Adropin is a regulator of endothelial NO synthase and NO release, and circulating adropin level decreases in obese patients. However, the association between exercise-training effects of arterial stiffness and circulating adropin level in obese subjects remains unclear. Hypothesis: This study aimed to determine the serum adropin level related to exercise-training effects of arterial stiffness in obese subjects. Methods: Eighteen Japanese obese subjects (age: 65.7 ± 1.6 years, % body fat: 34.8 ± 1.6 %) and nine Japanese non-obese subjects (age: 69.1 ± 1.0 years, % body fat: 19.9 ± 2.4 %) participated in this study. Obese subjects completed 8-week of aerobic exercise training (60-70% peak oxygen uptake [VO2peak] for 45 min, 3 days/week). Before and after the intervention, we evaluated plasma nitrite/nitrate (NOx) and serum adropin concentrations, carotid beta-stiffness as an indicator of arterial stiffness, and VO2peak as an index of cardiorespiratory fitness. VO2peak was measured using an incremental cycle exercise test on a cycle ergometer. Results: Serum adropin level in the obese subjects was lower than that in the non-obese subjects. After the 8-week intervention, VO2peak was significantly increased and carotid beta-stiffness was significantly decreased (P &lt; 0.05). Moreover, plasma NOx level and serum adropin level was significantly increased after the 8-week intervention (P &lt; 0.05). Additionally, the exercise training-induced reduction in beta-stiffness was negatively correlated with the training-induced changes in serum adropin (r = -0.481, P &lt; 0.05) and plasma NOx levels (r = -0.668, P &lt; 0.01). Furthermore, a significant correlation was observed between the training-induced changes in serum adropin and plasma NOx levels (r = 0.677, P &lt; 0.01). Conclusions: These results suggest that the plasma adropin level is increased by aerobic exercise training intervention and is associated with exercise training-induced alternation of arterial stiffness in obese subjects. Thus, the increase in adropin may participate in the exercise-induced reduction of arterial stiffness.
End-of-life care in patients with primary malignant brain tumors: A systematic literature review and analysis.
Authors: Tobias Walbert, Muhib Alam Khan
Journal: Journal of Clinical Oncology (2013)

e20703 Background: 80–85% of all adult brain tumors are high-grade glioma (HGG). HGG are typically treated with maximal surgical resection, followed by radiotherapy with concurrent and adjuvant chemotherapy. The median survival for anaplastic glioma is estimated to be 2-5 years and 15 months for patients with glioblastoma. Quality of life (QoL) has become an increasing important outcome assessed in clinical trials as well as in the standard care of brain tumor patients. Despite the inevitable disease trajectory, not much is known about symptoms and needs of brain tumor patients and their caretakers at the end of life. There appears to be a lack of published literature on this important aspect of neuro-oncology. Methods: A systematic literature search was conducted in PubMed and Cochrane covering the years between 1946 through 2012. In total, 7146 article citations were found. After first review 942 abstracts were obtained. Based on content 82 articles were examined separately by both authors and it was agreed to eliminate 67 of them because they did not include a significant number of primary brain tumor patients or the focus was not on end of life care and symptoms. Results: Only 7 of the retained articles contained specific patient data and did not just reflect opinions of authors or reviews of the topic. Only one study was performed prospectively. Three studies assessed symptom management in inpatients, 2 in outpatients and 2 in a combined setting. Studies included between 29 and 169 patients. Drowsiness and loss of consciousness was the most common symptom (85%–90%). Poor communication (64% and 90%), focal deficits (29%– 62%), seizures (3%–67%), dysphagia (10%–85%), headache (4%–62%), and fatigue (25%–67%) were also frequent. Interventions included hydration (87%-93%), urinary catheter (89%), steroids (62%-80%), anti-epileptic drugs (45%-76%), oxygen (48%), tube feeding (13%) and palliative sedation (13%). Conclusions: There is 1 prospective study and only a total of 7 studies describing detailed end of life symptoms. None of the studies addressed caregiver quality of life. More research is needed to develop purposeful interventions to address end of life symptoms and QoL in patients with HGG.
The Use of Steroid for Transcatheter Arterial Chemoembolization: To Relieve Symptoms or to Mask Adverse Events?
Authors: Gin‐Ho Lo
Journal: Hepatology (2018)

Lo G‐H. The Use of Steroid for Transcatheter Arterial Chemoembolization: To Relieve Symptoms or to Mask Adverse Events?. Hepatology. 2018;00:000–000. https://doi.org/10.1002/hep.30112LoG‐H. The Use of Steroid for Transcatheter Arterial Chemoembolization: To Relieve Symptoms or to Mask Adverse Events?. Hepatology. 2018;00:000–000. https://doi.org/10.1002/hep.30112 1 TO THE EDITOR: I read with interest the article by Ogasawara et al. regarding the use of dexamethasone to prevent the occurrence of fever, anorexia, abdominal pain, and nausea/vomiting after transcatheter arterial chemoembolization (TACE), so‐called postembolization syndrome (PES).(1) PES has affected a number of patients with advanced hepatocellular carcinoma. Drugs that could prevent PES would be welcomed by both clinicians and patients. The efforts to alleviate and reduce PES by the investigators should be applauded. However, the potential complications of using steroids should be seriously concerned. Hepatocellular carcinoma is well documented to be associated with a high incidence of cirrhosis. Peptic ulcers are frequently encountered in patients with cirrhosis.(2) It has been found that gastroduodenal lesions could be found in up to 65% of patients receiving TACE(2) and 3% of patients may have upper gastrointestinal hemorrhage.(3) On the other hand, bacterial infections have been noted to occur in 11% of patients receiving TACE without prophylactic antibiotics. All of these patients might present with PES after TACE. If PES is effectively prevented by steroids, these side effects may be masked as symptom‐free, leading to medical errors in delaying the diagnosis and management. Moreover, clinical events such as hypertension, ascites, pleural effusion, encephalopathy, and poor control of diabetes were actually more frequently encountered in patients receiving steroid therapy. If pooled together, these clinical events could possibly be significantly more often associated with the use of dexamethasone. Hence, the safety of reducing PES by the addition of steroid should be carefully evaluated before we can embrace this new policy. 2 Potential conflicts of interest Nothing to report. 3 Uncited references 4, 5.
Adiposity-Mortality Relationships in Type 2 Diabetes, Coronary Heart Disease, and Cancer Subgroups in the UK Biobank, and Their Modification by Smoking
Authors: David A. Jenkins, Jack Bowden, Heather A. Robinson, Naveed Sattar, Ruth J.F. Loos, Martin K. Rutter, Matthew Sperrin
Journal: Diabetes Care (2018)

OBJECTIVE The obesity paradox in which overweight/obesity is associated with mortality benefits is believed to be explained by confounding and reverse causality rather than by a genuine clinical benefit of excess body weight. We aimed to gain deeper insights into the paradox through analyzing mortality relationships with several adiposity measures; assessing subgroups with type 2 diabetes, with coronary heart disease (CHD), with cancer, and by smoking status; and adjusting for several confounders. RESEARCH DESIGN AND METHODS We studied the general UK Biobank population (N = 502,631) along with three subgroups of people with type 2 diabetes (n = 23,842), CHD (n = 24,268), and cancer (n = 45,790) at baseline. A range of adiposity exposures were considered, including BMI (continuous and categorical), waist circumference, body fat percentage, and waist-to-hip ratio, and the outcome was all-cause mortality. We used Cox regression models adjusted for age, smoking status, deprivation index, education, and disease history. RESULTS For BMI, the obesity paradox was observed among people with type 2 diabetes (adjusted hazard ratio for obese vs. normal BMI 0.78 [95% CI 0.65, 0.95]) but not among those with CHD (1.00 [0.86, 1.17]). The obesity paradox was pronounced in current smokers, absent in never smokers, and more pronounced in men than in women. For other adiposity measures, there was less evidence for an obesity paradox, yet smoking status consistently modified the adiposity-mortality relationship. CONCLUSIONS The obesity paradox was observed in people with type 2 diabetes and is heavily modified by smoking status. The results of subgroup analyses and statistical adjustments are consistent with reverse causality and confounding.